Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer

Clinical and Translational Medicine(2022)10.1002/ctm2.985Source: DataRank Database

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer is a research paper published in Clinical and Translational Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.06)OA: goldTopics (38)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Takamichi Yokoe ORCID,Yuta Kobayashi ORCID,Tomohiro Murakami,Peter J. Bostick,Yosef Shiloh ORCID

Live enrichment

PubMed:35839317 PMC:PMC9286529 OpenAlex:https://openalex.org/W4285499710

NIH HHS

Grant: S10 OD025017

National Science Foundation

Grant: 0722519

MRI: Acquisition of a Stimulated Emission Depletion (STED) Microscope for Nanoscopic Resolution of Biological Samples

National Institutes of Health

Grant: 1S10OD025017-01

Multiphoton Microscope for Deep Tissue Imaging

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

FWCI

1.06

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1002/ctm2.985

publisherhttps://doi.org/10.1002/ctm2.985

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.985

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/ctm2.985

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35839317

Fields of Study

interferon and immune responsesRNA modifications and cancerUbiquitin and proteasome pathways0301 basic medicine0303 health sciences03 medical and health sciencesCarrier ProteinsCisplatinDNA DamageHumansNuclear ProteinsTriple Negative Breast Neoplasms

MeSH Terms

Carrier ProteinsCisplatinDNA DamageHumansNuclear ProteinsTriple Negative Breast Neoplasms

Keywords

CisplatinTriple-negative breast cancerCancer researchBreast cancerMedicineOncologyDNA damageInternal medicineCancerBiologyChemotherapyDNAGeneticsMedicine (General)R5-920HumansNuclear ProteinsTriple Negative Breast NeoplasmsCarrier ProteinsLetter to the Editor

Sustainable Development Goals

SDG 0: Good health and well-being